bp3

163-bp3 is an effective photoaffinity probe and can be used as a target γ Secretory enzyme.

PROTAC HSP90 degrader BP3 potently and selectively degrades HSP90 through a CRBN-dependent mechanism. It effectively diminishes HSP90 protein levels in MCF-7 cells with a half-maximal degradation concentration (DC50) of 0.99 µM. Additionally, this compound impedes the proliferation of breast cancer cells [1].

BIBP3226 TFA is an effective and selective antagonist of neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor (Kis: 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF).

IGF2BP3-IN-1 is an inhibitor of IGF2BP3 (an RNA-binding protein) with an IC50 greater than 50 μM, suitable for cancer research.

GluR5-containing kainate receptor antagonist

UBP301 is a kainate receptor antagonist.

UBP310 (UBP 310) is a GLUK5 kainate receptor antagonist

BIBP3226 is a potent and selective antagonist for the Neuropeptide Y receptor (Y1) and the neuropeptide FF receptor (NPFF).

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

Cefaclor monohydrate (Cefaclorum) is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity.

Cefoxitin (Rephoxitin) is a broad-spectrum, orally available second-generation cephalosporins antibiotic. Cefoxitin interferes with the synthesis of bacterial cell walls. Its activity profile includes Gram-negative and Gram-positive bacteria, and is commonly used in abdominal cavity infections, pelvic infections, and certain types of gynecological infections, and is highly effective against anaerobic bacteria.

UMB298 is a potent and selective CBP/P300 bromodomain inhibitor that inhibits BRD4 with an IC50 of 5193nM.

MGB-BP-3 is a synthetic antibiotic with bactericidal activity that inhibits bacterial DNA replication and can be used to study recurrent C. difficile infections.

UBP 302 is an effective and selective GLUK5-subunit-containing kainate receptor antagonist (apparent Kd=402 nM) and displays very little affinity on GluK2 kainate receptors.

3BP-3580 is an inhibitor of fibroblast activation protein (FAP) with a pIC50 value of 8.6, utilized in cancer research.

CBP-307 is a selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator.

ABP-309 is a biochemical.

BIBP 3226 trifluoroacetate is a mixed non-peptide neuropeptide Y Y1(NPY Y1) and neuropeptide FF (NPFF) receptor antagonist (Kivalues are 1.1, 79, 108, > 1000, > 1000 and >1000 for rNPY Y1, hNPFF2, rNPFF, rNPY Y2, rNPY Y4and rNPY Y5respectively). Produces an anxiogenic-like effect in rats following i.c.v. administration.

BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

Cefaclor (Panoral) is a cephalosporin antibiotic.

Zimberelimab (GLS-010) is a humanized monoclonal antibody targeting PD-1, with antitumor activity. It blocks the interaction between PD-L1, PD-L2, and PD-1 on the cell surface, and is used in studies of cervical cancer and non-small cell lung cancer.

IACS-13909 (BBP-398), a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway.

SBP-3264 is a novel inhibitor of serine/threonine-protein kinases 3 and 4 (STK3 and STK4).

3BP-3940, a fibroblast activation protein (FAP)-targeting peptide, serves as a potent agent for theranostics. It is frequently conjugated with radionuclides to facilitate tumor diagnosis and therapy [1].